Update (June 9, 2026): Combination Oclacitinib and Lokivetmab After Monotherapy Failure in 44 Dogs

TL;DR. A 2026 retrospective study found that 61% of dogs failing both lokivetmab and oclacitinib monotherapy achieved adequate pruritus control with the combination, with a 61% mean reduction in pVAS and no adverse effects.

What just dropped

Bachtel JC and Snidow M published "Efficacy of Combination Oclacitinib and Lokivetmab Therapies After Monotherapeutic Failure in 44 Dogs: A Retrospective Study" in Veterinary Dermatology (April 2026; PMID 41189387; DOI 10.1111/vde.70034). The study enrolled 44 client-owned dogs at the Veterinary Referral Center of Colorado that had demonstrably failed both oclacitinib and lokivetmab as separate monotherapies. All were then treated with combination oclacitinib plus lokivetmab therapy, referred to as COLT.

Context

Canine atopic dermatitis (CAD) is frequently managed with either oclacitinib (Apoquel, JAK1 inhibitor) or lokivetmab (Cytopoint, anti-IL-31 monoclonal antibody). These two drugs target the itch pathway at different levels: lokivetmab neutralizes free IL-31 upstream, while oclacitinib inhibits the JAK1 signaling step downstream from IL-31 and other JAK-dependent cytokines (including IL-4, IL-13, and IL-31 receptor signaling). Some dogs fail to achieve adequate pruritus control on either agent alone, and management options for these refractory cases are limited.

What this changes in lokivetmab-cytopoint-canine-atopic-dermatitis (https://www.thevoyage.ai/forvets/knowledge/lokivetmab-cytopoint-canine-atopic-dermatitis)

Bachtel and Snidow 2026 provides the first structured evidence base for COLT in monotherapy-refractory CAD:

Key results:

• 27 of 44 dogs (61.4%) responded to COLT based on at least a 2 cm pVAS reduction plus clinician/owner consensus
• In responding dogs, mean pVAS (for the prior monotherapy phase) was 6.87 out of 10, falling to 2.67 out of 10 after COLT (61.1% reduction; p less than 0.0001)
• Zero adverse effects were attributed to the combination

Mechanistic rationale: oclacitinib inhibits JAK1-dependent signaling at the receptor level, while lokivetmab prevents IL-31 from binding its receptor in the first place. The combination may address cases where IL-31 levels overwhelm the inhibitory capacity of oclacitinib alone, or where non-IL-31 JAK-dependent cytokines drive residual itch not controlled by lokivetmab.

Limitations: single-center retrospective design; lack of a control arm; absence of prospective randomization. These findings are best interpreted as proof-of-concept data supporting a prospective trial, not definitive evidence for routine combination use.

References

1. Bachtel JC, Snidow M. Efficacy of Combination Oclacitinib and Lokivetmab Therapies After Monotherapeutic Failure in 44 Dogs: A Retrospective Study. Vet Dermatol. 2026;37(2):287-292. https://pubmed.ncbi.nlm.nih.gov/41189387/

Voyage Clinical Desk

From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=lokivetmab-cytopoint-canine-atopic-dermatitis

Changelog

• 2026-06-09: First published.

Related reads

• Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence